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The Wnts comprise a large class of secreted proteins that control essential developmental processes such as embryonic
patterning, cell growth, migration, and differentiation. In the most well-understood ‘‘canonical’’ Wnt signaling
pathway, Wnt binding to Frizzled receptors induces b-catenin protein stabilization and entry into the nucleus, where it
complexes with T-cell factor/lymphoid enhancer factor transcription factors to affect the transcription of target genes.
In addition to the canonical pathway, evidence for several other Wnt signaling pathways has accumulated, in particular
for Wnt5a, which has therefore been classified as a noncanonical Wnt family member. To study the alternative
mechanisms by which Wnt proteins signal, we purified the Wnt5a protein to homogeneity. We find that purified Wnt5a
inhibits Wnt3a protein–induced canonical Wnt signaling in a dose-dependent manner, not by influencing b-catenin
levels but by downregulating b-catenin–induced reporter gene expression. The Wnt5a signal is mediated by the
orphan tyrosine kinase Ror2, is pertussis toxin insensitive, and does not influence cellular calcium levels. We show that
in addition to its inhibitory function, Wnt5a can also activate b-catenin signaling in the presence of the appropriate
Frizzled receptor, Frizzled 4. Thus, this study shows for the first time that a single Wnt ligand can initiate discrete
signaling pathways through the activation of two distinct receptors. Based on these and additional observations, we
propose a model wherein receptor context dictates Wnt signaling output. In this model, signaling by different Wnt
family members is not intrinsically regulated by the Wnt proteins themselves but by receptor availability.
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Introduction
Wnt signaling controls a variety of adult and developmen-
tal processes, largely by modulating gene transcription [1].
The necessity of precise regulation to prevent the inappro-
priate activation of Wnt signaling is underscored by the fact
that misregulation of several components of the canonical
Wnt signal transduction pathway leads to tumorigenesis [2].
Wnt signaling is also thought to play a key role in controlling
stem cell fate [3]. Thus, understanding the mechanisms that
regulate Wnt signaling is of critical importance.
Wnt proteins are found in all metazoan organisms and as
many as 19 mammalian homologs are known (Wnt home
page: http://www.stanford.edu/;rnusse/wntwindow.html).
While homologs have a high degree of sequence similarity,
expression of different Wnt proteins can lead to vastly
different developmental outcomes. In the most well-under-
stood ‘‘canonical’’ Wnt/b-catenin signaling pathway, in the
absence of a Wnt ligand, the main mediator of the signal
relay, b-catenin, is bound in a cytosolic protein complex
containing Axin, the adenomatous polyposis coli gene
product (APC), glycogen synthase kinase-3b (GSK-3b), and
other proteins. Axin and APC serve as scaffolding proteins
that enable GSK-3b to phosphorylate b-catenin, thereby
targeting it for ubiquitination by bTrCP (beta-transducin
repeat–containing homologue protein) and subsequent deg-
radation in the proteasome. Cytosolic b-catenin protein
levels are thus kept low in the absence of ligand stimulation.
Wnt protein binding to cognate Frizzled (Fz) and low-density
lipoprotein (LDL) receptor–related protein (LRP)5/6 core-
ceptors leads to the activation of the Dishevelled (Dvl)
protein, which then inhibits GSK-3b–mediated phosphoryla-
tion of b-catenin. Cytosolic b-catenin protein becomes
stabilized and newly synthesized b-catenin is able to accumu-
late and then translocate to the nucleus where binding to T-
cell factor (TCF)/lymphoid enhancer factor (LEF) transcrip-
tion factors leads to the activation of target gene expression
[1].
Prior to the discovery of the Fz and LRP coreceptors, Wnt
proteins were classiﬁed into two functional groups based on
the observation that ectopic expression of some Wnts, such as
Wnt1 and Wnt3a, is sufﬁcient to induce a secondary dorsal-
ventral axis in Xenopus embryos and morphologically trans-
form C57MG mouse mammary epithelial cells, whereas
expression of ‘‘Wnt5a class’’ Wnts, including Wnts 4, 5a, and
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PLoS BIOLOGY11, is not sufﬁcient [4–8]. One hypothesis for how the
structurally similar, although functionally distinct, extracel-
lular Wnt ligands trigger different developmental outcomes is
that the two classes of Wnts signal via different intracellular
pathways. Indeed, experiments in zebraﬁsh and Xenopus
embryos using mRNA injection to activate Wnt signaling
have suggested that expression of Wnt5a stimulates intra-
cellular calcium (Ca
2þ) ﬂux leading to the activation of Ca
2þ–
dependent effector molecules such as calcium/calmodulin–
dependent kinase II (CamKII), nuclear factor associated with
T cells (NFAT), and protein kinase C (PKC) in a pertussis
toxin (PTX)–sensitive manner [9–12]. However, due to the
lack of active soluble Wnt5a protein, direct activation of
‘‘Wnt/Ca
2þ’’ pathway signaling in mammalian cell culture
systems has not been fully investigated.
In addition to activating alternative signaling pathways,
Wnt5a may also inhibit Wnt/b-catenin signaling. Early experi-
ments in Xenopus embryos showed that coexpression of
XWnt5a with XWnt8 abrogates the ability of XWnt8 to
induce a secondary axis [13–15]. Wnt5a knockout mice show
increased b-catenin signaling in the distal limb, indicating
that Wnt5a may inhibit b-catenin stabilization [16]. In
contrast, experiments from Ishitani et al. have shown that
Wnt5a-induced Ca
2þ ﬂux blocks canonical signaling down-
stream of b-catenin stabilization by inhibiting TCF-mediated
transcription in a PTX-sensitive manner [16–18]. As Wnt5a
heterozygous mice develop myeloid leukemias and B-cell
lymphomas, an intriguing hypothesis is that Wnt5a serves as a
tumor suppressor in part by preventing excess Wnt/b-catenin
signaling [19].
While most Wnt signaling has been attributed to the
activation of Fz receptors, an alternative possibility is that
Wnts carry out their diverse roles by signaling via different
receptors. One such receptor is Ror2, an orphan tyrosine
kinase possessing an extracellular cysteine-rich Wnt binding
domain (CRD) [20–23]. Wnt5a and mRor2 have overlapping
expression patterns, their knockout phenotypes are similar,
and recently mRor2 has been shown to act synergistically with
Wnt5a to activate Jun kinase [23–26]. Thus, Wnt5a may be
mediating its inhibitory role through the activation of this
novel receptor.
There are conﬂicting data in the literature regarding the
mechanism by which Wnt5a and other so-called noncanonical
Wnt protein signals. To understand how signals like Wnts
inﬂuence cells, one must discriminate between early and late
effects and measure those effects in a concentration-depend-
ent manner. To that end, we have puriﬁed active Wnt5a
protein and established quantitative assays for signaling. We
show for the ﬁrst time that soluble Wnt5a protein is able to
directly inhibit canonical Wnt signaling. Treatment of cells
with puriﬁed protein over short time intervals is sufﬁcient to
inhibit the activation of the TCF/LEF-driven luciferase
reporter SuperTopFlash (STF). The inhibition observed is
dose responsive, occurs downstream of b-catenin stabiliza-
tion, and is PTX insensitive. We also show that an alternative
Wnt receptor, Ror2, is required for Wnt5a-mediated inhib-
ition of canonical signaling and that the extracellular,
cysteine-rich Wnt binding domain and intracellular, cyto-
plasmic domain are crucial for the receptor’s inhibitory
function. Whereas Wnt5a protein is usually associated with
noncanonical Wnt signaling, we show that Wnt5a can activate
Wnt/b-catenin signaling in the presence of Fz 4 and LRP5.
Based on these and other observations, we propose a model
wherein receptor context dictates Wnt signaling output,
suggesting a new layer of regulatory complexity in the Wnt
signaling cascade with important implications in develop-
ment and disease.
Results
Purification of Wnt5a Protein: Evidence that It Is Cleaved
from a Precursor
We puriﬁed the Wnt5a protein from cells overexpressing
the mouse Wnt5a gene using methods derived from those
developed for other members of the Wnt family with several
modiﬁcations (Figure1A) [27]. Throughout the puriﬁcation,
we followed the Wnt5a protein using an antibody that detects
Wnt5a on a Western blot. Later steps in the puriﬁcation were
also monitored by activity assays (see below). To unambigu-
ously identify the puriﬁed protein as the product of the
Wnt5a gene, we determined the amino-terminal sequence. We
f o u n dt h a tt h em a t u r ep r o t e i ns t a r t sw i t has e q u e n c e
IIGAQPLCSQLAGLSQGQKKL, a sequence beginning 62
amino acids downstream from the predicted initiator
methionine of Wnt5a and 24 amino acids from the predicted
signal cleavage site between amino acids 37 and 38 [28]. While
all Wnt proteins contain signal sequences required for
secretion from cells, generally they are not internally cleaved
at a site downstream from the signal sequence. The
exception, interestingly, is the Drosophila ortholog of Wnt5a;
DWnt5 protein is made as a precursor of more than 1,000
amino acids weighing 140 kDa and cleaved into a smaller
mature protein of 80 kDa [29]. It is not known whether the
processing of the Wnt5a molecule involves speciﬁc proteases.
We ﬁnd that, similar to other Wnt proteins that we have
puriﬁed, the Wnt5a protein is hydrophobic as it requires
detergent to stay in solution and partitions in a detergent
phase when subjected to extraction (unpublished data) [27].
We presume that the protein, like Wnt3a, is modiﬁed by the
covalent attachment of a palmitate, but we have not
examined this further. Signiﬁcantly, the cysteine residue that
is modiﬁed by palmitoylation in Wnt3a is conserved in
Wnt5a, even after the internal cleavage of the protein.
Purified Wnt5a Protein Inhibits Canonical Wnt Reporter
Activation
Standard readouts for the activity of various Wnt family
members include an increase in the level of the b-catenin
protein and the activation of reporter genes, in particular,
the Topﬂash reporter that contains TCF binding sites
upstream of a luciferase transgene. We found that when
transiently transfected into 293 cells, the SuperTopﬂash (STF)
luciferase reporter variant [30] is robustly activated in
response to Wnt3a treatment and exhibits dose-dependency.
As shown in Figure1B, Wnt3a protein treatment induces a
100-fold increase in reporter activation and a linear dose
response when the concentration is lowered. In accordance
with other groups, we observe that Wnt5a protein by itself
does not lead to the activation of the STF reporter in 293
cells, nor does it alter levels of b-catenin protein (Figures 1C
and 2A) [16,31]. Based on reports from Ishitani et al. and
others [14,17,32,33], we then tested whether the addition of
Wnt5a protein could inhibit Wnt3a-induced reporter activity.
Using a concentration of Wnt3a protein within the linear
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added to cells concomitantly with Wnt3a. As shown in Figure
1C, Wnt5a elicits a dose-responsive decrease in Wnt3a-
mediated reporter activation.
Wnt5a protein inhibits Wnt3a signaling at the earliest time
points following reporter activation. When cells are pre-
treated with Wnt3a protein for 1 or 3 h prior to Wnt5a
treatment, Wnt5a can inhibit Wnt3a-induced reporter
activation within 1 h of exposure (Figure 1D). In addition,
Wnt5a pretreatment of cells for 8 h followed by washing has
no effect on either Wnt3a-induced STF reporter activation or
Wnt5a-mediated inhibition, suggesting that Wnt5a does not
induce the accumulation of an inhibitory factor (Figure 1E).
These data taken together indicate that puriﬁed Wnt5a
Figure 1. Purified Wnt5a Protein Inhibits Canonical Wnt Reporter Activation
(A) Coomassie blue–stained gel showing the Wnt5a protein purification scheme.
(B) The 24-h Wnt3a protein treatment activates the STF luciferase reporter in a dose-responsive manner.
(C) Concomitant Wnt5a protein treatment inhibits Wnt3a-induced STF reporter activation.
(D) Time-course analysis of Wnt5a-mediated inhibition of Wnt3a. At approximately 40 h post-transfection, cells were treated with Wnt3a protein for 0, 2,
4, 6, or 8 h alone or in conjunction with Wnt5a at t ¼0, t ¼1h ,o rt ¼ 3 h. (Filled diamonds indicate Wnt3a treatment alone; open diamonds indicate
Wnt3a treatment at t¼0 plus Wnt5a protein treatment at t¼0; filled triangles indicate Wnt3a treatment at t¼0 plus Wnt5a protein treatment at t¼1;
open circles indicate Wnt3a treatment at t ¼ 0 plus Wnt5a protein treatment at t ¼ 3.)
(E) Wnt5a pretreatment does not enhance its inhibitory activity. At 24 h post-transfection, cells were pretreated with vehicle or Wnt5a protein (200 ng/
ml) for 8 h. Cells were then treated with vehicle, Wnt3a alone, or Wnt3a concomitantly with Wnt5a for an additional 24 h, and luciferase assay was
performed. (Filled squares indicate cells that were pretreated with vehicle for 8 h prior to Wnt addition; open squares indicate cells pretreated with
Wnt5a protein for 8 h prior to Wnt addition.) Unless stated in text, luciferase activity was measured 48 h after transfection, approximately 24 h after Wnt
treatment, and results are shown as the average fold change 6 SD in luciferase activity over transfected, untreated negative controls.
DOI: 10.1371/journal.pbio.0040115.g001
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in a potentially post-translational fashion.
Wnt5a Does Not Affect b-Catenin Protein Stabilization
One possible explanation for the observed abrogation of
reporter activation is that Wnt5a protein competes with
Wnt3a for Fz receptor binding sites. Alternatively, Wnt5a has
been proposed to inhibit canonical Wnt signaling via
upregulation of Siah-2, which targets b-catenin for bTrCP-
independent proteasomal degradation [16]. In both of these
models, b-catenin protein levels should be reduced following
concomitant Wnt5a treatment compared to Wnt3a protein
treatment alone; in the former case, signal transduction is
blocked at the level of the receptor, whereas in the latter, any
b-catenin protein stabilized due to Wnt3a signal activation
should be appreciably degraded by the opposing effects of
Wnt5a.
To assess the levels of accumulated b-catenin protein, we
prepared cytosolic extracts from 293 cells treated for 3 h with
Wnt3a protein, Wnt5a protein, or both. Cellular fractiona-
tion is necessary to ensure that only cytosolic b-catenin
protein stabilized due to active Wnt signaling is observed as
opposed to the relatively stable membrane-associated pool of
b-catenin protein. Although a particularly low dose of Wnt3a
protein (10 ng/ml) was used in this analysis to ensure that
subtle differences in b-catenin protein levels could be
discerned, no appreciable reduction in b-catenin accumu-
lation was observed (Figure 2A), even when concentrations of
Wnt5a protein (200 ng/ml) sufﬁcient to inhibit the STF
reporter 5-fold were used. These data show that the Wnt3a
Figure 2. Wnt5a Does Not Affect b-Catenin Stabilization
(A) Wnt5a protein treatment does not affect cytosolic b-catenin protein levels. The 293 cells were treated for 3 h with the indicated concentrations of
Wnt proteins and then hypotonically lysed for Western blot analysis of cytosolic fractions.
(B) Wnt5a protein treatment does not alter b-catenin cellular localization. Cells grown on coverslips were treated with the indicated concentrations of
Wnt proteins for 6 h and then fixed and stained as described in the text. Membrane localized b-catenin is indicated by arrowheads; membrane and
cytosolic staining is indicated by arrows.
DOI: 10.1371/journal.pbio.0040115.g002
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Receptor Context Dictates Wnt5a Signalingsignal is initiated in the presence of Wnt5a protein,
indicating that Wnt5a does not efﬁciently compete with
Wnt3a for receptor binding sites.
To determine whether Wnt5a treatment inhibits b-catenin
nuclear entry, cell-staining experiments were performed
(Figure 2B). The 293 cells treated with vehicle or Wnt5a
protein alone display a membrane-associated staining pat-
tern (arrowheads) consistent with b-catenin’s role in cell
adhesion. By contrast, cells treated with Wnt3a protein alone
appeared brighter than vehicle-treated cells, with b-catenin
observed in the cytoplasm and nuclei (arrows). No signiﬁcant
difference in b-catenin signal intensity or localization was
observed when cells were treated with Wnt3a in combination
with Wnt5a protein (Figure 2B). The observation that Wnt3a-
mediated b-catenin stabilization and nuclear entry appear
unaffected by Wnt5a treatment suggests that upregulation of
Siah-2, and subsequent degradation of b-catenin, is not the
primary mechanism of Wnt5a protein-mediated inhibition of
gene transcription in these cells.
Wnt5a-Mediated Inhibition of Canonical Signaling Is Not
Associated with Wnt-Stimulated Ca
2þ Flux
Past studies in zebraﬁsh and Xenopus embryos have
suggested that overexpression of Wnt5a can trigger intra-
cellular Ca
2þﬂux, leading to the activation of Ca
2þ-dependent
effector molecules such as CamKII [9,34,35]. It has been
proposed that active CamKII protein can then initiate the
mammalian TGF-b–activated kinase 1(TAK)/Nemo-like kinase
(NLK) mitogen-activated protein kinase signaling cascade,
resulting in NLK-mediated phosphorylation of TCF/LEF
transcription factors. This phosphorylation of TCF/LEF
prevents the b-catenin–TCF/LEF transcriptional complex
from binding to DNA [17,18,36]. In this model, inhibition of
Wnt/b-catenin signaling due to Wnt5a-stimulated Ca
2þ ﬂux
occurs downstream of b-catenin stabilization and at the level
of TCF-mediated transcription. In a variety of organisms and
assays, Ca
2þ signaling induced by Wnts has consistently been
shown to be PTX sensitive, as the Fz receptor described as
transmitting the inhibitory Wnt signal (RFz2) is thought to be
coupled to a PTX-sensitive G protein [8,37,38].
To determine whether Wnt5a protein inhibits b-catenin
signaling via the direct activation of intracellular Ca
2þ ﬂux
downstream of heterotrimeric G proteins, 293 cells tran-
siently transfected with the STF reporter were treated with 50
ng/ml W3a protein and increasing doses of Wnt5a protein
following 24-h pretreatment with vehicle or 100 ng/ml (0.1
lM) PTX. Figure 3A shows that Wnt5a protein-mediated
inhibition of the STF reporter was not affected by PTX
treatment. The PTX used was active in these cells, as
lysophosphatidic acid (LPA) treatment of cells following
pretreatment with PTX was unable to stimulate the phos-
phorylation of the mitogen-activated protein kinases Erk1
and Erk2, a known PTX-sensitive process in 293 cells [39]
(Figure 3B). These data are consistent with Topol et al.’s [16]
ﬁndings that overexpression of a dominant negative version
of CamKII, and treatment of cells with a speciﬁc inhibitor of
CamKII, does not perturb Wnt5a-mediated inhibition of Wnt/
b-catenin signaling in 293 cells.
Wnt5a protein was also assayed for its ability to directly
stimulate intracellular calcium ﬂux. Figure 3C shows that
Wnt5a protein treatment at high doses does not alter the
intracellular concentration of Ca
2þ in 293 cells, although
subsequent ionomycin treatment of the same cells promotes
robust Ca
2þ ﬂux. Similar results were observed in 293 cells
stably expressing mouse Fz4 (mFz4); a Wnt receptor thought
to be involved in Wnt-stimulated calcium ﬂux (Figure 3C)
[40]. In addition, transient treatment with Wnt5a protein
does not activate other Ca
2þ-sensitive reporter constructs
such as an NFAT-responsive luciferase reporter (unpublished
data). These data taken together strongly suggest that Wnt-
stimulated Ca
2þ ﬂux is not the direct mechanism utilized by
Wnt5a to inhibit canonical Wnt signaling.
Wnt5a Protein Activates b-Catenin Signaling Depending
on Receptor Context
Although we show that Wnt5a protein can inhibit canon-
ical Wnt signaling, the question remains of whether Wnt5a
can activate Wnt/b-catenin signaling in mammalian systems.
Multiple Fz receptors, including mFz4, mFz6, mFz7, and
mFz8, were assayed for their ability to transduce Wnt5a-
mediated canonical Wnt signaling (unpublished data). We
f o u n dt h a tW n t 5 ac o u l di n d e e da c t i v a t eW n t / b-catenin
signaling when cells overexpressed mFz4; none of the other
overexpressed receptors could transduce the Wnt5a signal.
Western blot analysis of cytosolic extracts probed for b-
catenin (Figure 4A) shows that while Wnt5a has no effect on
cytosolic b-catenin levels in the parental 293 cell line, Wnt5a
can induce modest b-catenin accumulation in cells stably
expressing a FLAG-tagged mFz4 construct (293Fz4). These
results are in accordance with observations by Umbhauer et
al. [41] that coinjection of Xwnt5a RNA with Xfz4 RNA leads
to the synergistic activation of Wnt/b-catenin target genes in
Xenopus animal caps.
We next tested whether Wnt5a could activate the STF
reporter in 293Fz4 cells. Neither Wnt5a protein treatment at
high doses nor transfection of Wnt5a DNA into cells
expressing mFz4 could activate the STF reporter. However,
as shown in Figure 4B, when LRP5 is coexpressed with mFz4,
Wnt5a protein is able to activate the luciferase reporter.
Thus, Wnt5a can activate TCF/b-catenin signaling given the
expression of the appropriate receptors. Interestingly, Wnt5a
is unable to activate the STF reporter in 293Fz4 cells
transiently transfected with LRP6, indicating the speciﬁcity
of the Wnt5a/Fz4/LRP5 signaling complex (unpublished data).
To determine whether Wnt5a protein can inhibit Wnt3a-
mediated STF reporter activation in 293Fz4 cells, 293 and
293Fz4 cells were transiently transfected with the STF
reporter and then treated with Wnt proteins over the course
of 24 h. Whereas Wnt5a protein potently inhibits the STF
reporter in parental 293 cells, Wnt5a no longer inhibits
Wnt3a-induced reporter activation in 293Fz4 cells (Figure
4C). This effect was speciﬁc to mFz4, as stable expression of
mFz8 was not sufﬁcient to abrogate Wnt5a-mediated inhib-
ition of STF reporter activation (Figure 4D). Additionally,
Wnt5a does not stabilize b-catenin protein in the presence of
mFz8 (unpublished data). Thus, speciﬁcally in the context of
mFz4 and LRP5 expression, Wnt5a is unable to inhibit
Wnt3a-mediated b-catenin signaling and instead induces b-
catenin accumulation and STF reporter activation.
An Alternative Wnt Receptor, mRor2, Mediates Wnt5a’s
Inhibitory Activity
One explanation for why Wnt5a is unable to inhibit Wnt3a-
mediated b-catenin signaling when mFz4 is overexpressed is
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may titrate available Wnt5a protein away from an alternative
receptor carrying out its inhibitory function. To investigate
this hypothesis, we turned to the orphan receptor mRor2, a
single-pass transmembrane tyrosine kinase with proposed
kinase-dependent and -independent activities [25,42]. mRor2
is an appealing candidate receptor mediating Wnt5a’s
inhibitory activity because Wnt5a and mRor2 have over-
lapping expression patterns, their knockout phenotypes are
similar, and mRor2 has been shown previously to act
synergistically with Wnt5a to activate Jun kinase [22–26]. In
addition, CAM-1, the C. elegans Ror2 homolog, has been shown
to inhibit canonical Wnt signaling–mediated cell migration,
although the Wnt ligand mediating this inhibition remains to
be determined [21].
To determine whether Wnt5a mediates its inhibitory
effects through the mRor2 receptor, 293 cells stably express-
ing the full-length mRor2 receptor (293mRor2) were treated
with Wnt proteins over the course of 24 h. As shown in Figure
5A, Wnt3a protein treatment robustly activates the STF
reporter in the presence of mRor2. However, at every time
point measured, Wnt5a protein-mediated inhibition of Wnt/
b-catenin signaling is synergistically enhanced by mRor2
overexpression as compared to the parental cell line
(compare to Figure 4C and see Figure S1).
We next assayed whether mRor2 was carrying out its
inhibitory function through direct binding to Wnt5a. Two
variants of the extracellular cysteine-rich Wnt binding
domain (CRD) of mRor2 were cloned in frame amino-
terminal to an immunoglobulin heavy chain domain (IgG)
as previously described and expressed in 293 cells [43]. One
variant is comprised of the Ror2 CRD alone cloned down-
stream of an exogenous signal sequence (Ror2 CRD-IgG); the
other variant utilizes the endogenous Ror2 signal sequence
and possesses the full amino terminus of the Ror2 protein
ending at the carboxyl terminus of the CRD (Ror2 NT CRD-
IgG). The secreted mRor2 CRD-IgG fusion proteins were then
puriﬁed from conditioned media, bound to protein A beads,
and tested for their ability to bind to puriﬁed Wnt proteins.
The Smoothened receptor is a Fz family member that
Figure 3. Wnt5a-Mediated Inhibition of Canonical Signaling Is Not Associated with Wnt-Stimulated Ca
2þ Flux
(A) Wnt5a-mediated inhibition is PTX insensitive. At 24 h post-transfection, 293 cells were pretreated with vehicle or 100 ng/ml PTX for 24 h. Cells were
then treated with indicated Wnt proteins concomitantly with vehicle or PTX for an additional 24 h, and luciferase assay was performed.
(B) PTX is active in 293 cells as PTX pretreatment of cells inhibits LPA-induced Erk1,2 activation. The 293 cells were pretreated with 100 ng/ml PTX for 24
h and then treated with 10 lM LPA or vehicle for 10 min. Western blot analysis was then performed on total cell lysates using anti–phospho-Erk1,2
antibody. Membrane was stripped and reprobed for total Erk1,2 as a loading control.
(C) Wnt5a protein does not directly stimulate intracellular Ca
2þ flux. The 293 and 293Fz4 cells were loaded with Fura-2-dextran and then monitored for
changes in intracellular Ca
2þ concentration as determined by the change in 340/380 excitation wavelength ratio following Wnt5a (500 ng/ml) and
subsequent ionomycin treatment. Data represent the average 340/380 excitation wavelength ratio of three or more independent cells within the same
field 6 SD. Wnt5a has little effect on the ratio over the 15-min time course, whereas ionomycin treatment rapidly and robustly induces Ca
2þ flux in
these cells. Prolonged treatment with Wnt5a (up to 1 h) did not result in changes in intracellular Ca
2þ levels (unpublished data).
DOI: 10.1371/journal.pbio.0040115.g003
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Wnt signaling, it functions exclusively Hedgehog signal
transmission. As a negative control, puriﬁed Smoothened
(Smo) CRD-IgG protein was also bound to beads and assayed
for Wnt binding. Figure 5B shows that Wnt5a protein
speciﬁcally binds to the puriﬁed Ror2 and Fz4 CRD domains,
whereas only background binding to the Smoothened CRD
occurs. Wnt3a protein shows speciﬁc binding only to the Fz4
CRD-IgG protein (unpublished data).
We next utilized a Ror2 deletion construct that lacks the
extracellular cysteine-rich Wnt-binding domain
(mRor2DCRD) to determine whether the CRD domain was
necessary for Wnt5a signal transmission. When transiently
transfected into 293 cells in conjunction with the STF
reporter, mRor2DCRD does not enhance Wnt5a-mediated
inhibition of the STF reporter (Figure 5C). Thus, the CRD
domain binds directly to Wnt5a and is required for Ror2 to
transduce Wnt5a’s inhibitory activity.
Expression of mRor2 Is Required for Wnt5a-Mediated
Inhibition of Canonical Signaling
We next tested whether increased mRor2 expression was
necessary to shift the balance of Wnt5a-mediated activation
versus inhibition of Wnt/b-catenin signaling in cells over-
expressing mFz4. 293 and 293Fz4 cells were transiently
transfected with the STF reporter and mRor2 and then
treated with the indicated Wnt proteins. Figure 6A shows that
Wnt5a-induced reporter activation in the presence of mFz4
and LRP5 is abrogated when mRor2 is expressed. In addition,
while Wnt5a protein is unable to inhibit Wnt/b-catenin
signaling in the presence of mFz4, as compared to parental
293 cells, mRor2 overexpression synergistically enhances
Wnt5a’s ability to inhibit the reporter gene in both cell lines.
Figure 4. Wnt5a Protein Activates b-Catenin Signaling Depending on Receptor Context
(A) Wnt5a treatment leads to b-catenin stabilization specifically in cells expressing mFz4. The 293 and 293Fz4 cells were treated with Wnt proteins and
then assayed for cytosolic b-catenin protein accumulation via Western blot analysis.
(B) Wnt5a treatment activates the STF reporter when LRP5 is coexpressed. At 24 h post-transfection with STF reporter and LRP5 or empty vector, 293Fz4
cells were treated with increasing concentrations of Wnt5a protein for an additional 24 h, and luciferase assay was performed as described in Figure 1.
(C) Wnt5a does not inhibit Wnt3a-mediated reporter activation in 293Fz4 cells. The 293 and 293Fz4 cells were treated with Wnts as indicated 24 h post-
transfection with reporters, and luciferase assay was performed.
(D) Loss of Wnt5a-mediated reporter inhibition is specific to mFz4 overexpression. The 293, 293Fz4, and 293Fz8 cells were treated with the indicated
Wnts for 24 h, 24 h post-transfection, and then luciferase assay was performed. Wnt5a maintains inhibitory activity when mFz8, but not mFz4, is
overexpressed.
DOI: 10.1371/journal.pbio.0040115.g004
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Receptor Context Dictates Wnt5a SignalingOnce again, inhibition of Wnt3a-mediated reporter activa-
tion was observed only in the presence of Wnt5a; mRor2
expression alone did not reduce Wnt3a-mediated reporter
activation, indicating that the inhibitory activity is dependent
on the presence of Wnt5a.
Wnt5a’s inhibitory activity was also tested in another cell
line, mouse L cells. Whereas Wnt5a protein treatment in
parental 293 cells robustly inhibits the Wnt3a-mediated
activation of the STF reporter, Wnt5a treatment has little
to no inhibitory affect in L cells (Figure 6B). To assess
whether this is due to reduced expression of mRor2, L cells
were transfected with mRor2 and then treated with Wnt
proteins. As shown in Figure 6B, when mRor2 is overex-
pressed, Wnt5a protein potently inhibits the Wnt3a-induced
reporter activation in L cells. Again, mRor2 expression has no
inhibitory effect on Wnt3a-stimulated reporter activation in
the absence of Wnt5a. Although Wnt5a is able to activate the
luciferase reporter in L cells stably expressing mFz4 and
transiently transfected with LRP5, mRor2 cotransfection
effectively inhibits Wnt5a’s canonical signaling ability (Figure
6B).
Quantitative RT-PCR analysis was performed to ascertain
the expression of Ror2 in 293 and L cells. A speciﬁc Ror2
transcript in the L cell sample did not emerge until after 40
cycles of ampliﬁcation, indicating that Ror2 is expressed in
almost immeasurably low abundance in L cells. Quantiﬁca-
tion of the real-time data revealed that Ror2 transcripts were
over 700 times more abundant in 293 cells than in L cells
(Figure 6C). mRor2 expression thus appears to be required
for Wnt5a-mediated inhibition of Wnt/b-catenin signaling in
mouse L cells.
It has been proposed that the C. elegans Ror protein CAM-1
has tyrosine kinase–independent functions [42,44] and that
Xenopus XRor2 can function in the absence of its cytoplasmic
Figure 5. An Alternative Wnt Receptor, mRor2, Mediates Wnt5a’s Inhibitory Activity
(A) Wnt5a synergizes with mRor2 to inhibit Wnt3a-mediated reporter activation. The 293 cells stably expressing exogenous mRor2 (293Ror2) were
treated with Wnts as indicated, 24 h post-transfection with reporters, and luciferase assay was performed as outlined in Figure 1.
(B) Wnt5a binds directly to the Fz4 and mRor2 CRD domains. Wnt5a protein specifically binds to the purified mFz4 and mRor2 CRDs; only background
binding to the Smoothened CRD negative control is observed. While it may appear that Wnt5a binds to a similar extent to the Ror2 CRDs and Smo CRD,
the input levels of the Smo CRD-IgG exceeded the Ror2 CRD-IgG levels, accounting for the increased background binding Smo CRD-IgG.
(C) The mRor2 CRD domain is required for mediating Wnt5a inhibitory activity. The 293 cells were transiently transfected with reporters along with
empty vector, mRor2, or mRor2DCRD constructs, treated with Wnts as described in text 24 h post-transfection for an additional 24 h, and then luciferase
assay was performed as outlined in Figure 1.
DOI: 10.1371/journal.pbio.0040115.g005
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Receptor Context Dictates Wnt5a SignalingFigure 6. Expression of mRor2 Is Required for Wnt5a-Mediated Inhibition of Canonical Signaling
(A) In 293 cells, mRor2 overexpression inhibits Wnt5a-mediated activation of the STF reporter. The 293 and 293Fz4 cells were transiently transfected
with the reporters and LRP5 with or without mRor2 and then treated with Wnt proteins for 24 h, 24 h post-transfection. Overexpression of wild-type
mRor2 inhibits Wnt5a-mediated activation of the STF reporter as well as allowing Wnt5a to inhibit Wnt3a-mediated STF reporter activation in 293Fz4
cells.
(B) mRor2 overexpression inhibits Wnt5a-mediated activation of the STF reporter and allows Wnt5a to block Wnt3a-induced STF reporter activation in
mouse L cells. L and LFz4 cells were transiently transfected with the reporters and LRP5 with or without mRor2 and then treated with Wnt proteins for
24 h, 24 h post-transfection.
(C) Quantitative real-time PCR analysis of Ror2 expression in 293 and L cells. Reverse transcription followed by 45 cycles of quantitative real-time
amplification of 293 cell RNA reveals a robust Ror2 product that is over 700 times more abundant than that produced from RNA derived from mouse L
cells. Hprt quantification serves as an internal normalization control and RNA derived from 293Ror2 and LRor2 cells serves as a positive control for the
reaction. The products from the PCR analysis are displayed below the charted quantitative data.
(D) The cytoplasmic domain of mRor2 is required for its inhibitory function. Expression of a membrane-tethered variant of mRor2 possessing the
extracellular domain of mRor2 fused to a GPI linkage (mRor2-GPI) reduces Wnt5a’s ability to inhibit Wnt3a induced canonical Wnt signaling as well as
inhibits wild type mRor29s ability to enhance Wnt5a-mediated inhibition.
(E) Expression of a membrane-tethered variant of mRor2 (mRor2-TM) that contains the extracellular and transmembrane domains of mRor2, but lacks
the cytoplasmic domain, does not enhance Wnt5a mediated inhibition of canonical Wnt signaling. Expression of mRor2-TM reduces Wnt5a’s ability to
inhibit Wnt3a-induced canonical Wnt signaling when wild-type mRor2 is overexpressed. Western blot analysis shows that wild-type mRor2 levels do not
change when the truncated mRor2 variants are coexpressed.
DOI: 10.1371/journal.pbio.0040115.g006
PLoS Biology | www.plosbiology.org April 2006 | Volume 4 | Issue 4 | e115 0578
Receptor Context Dictates Wnt5a Signalingdomain [45]. We thus created a membrane-tethered variant of
mRor2 (mRor2-GPI) to assay whether mRor2 could still
function in the absence of its transmembrane and cytoplas-
mic domains. Expression of mRor2-GPI reduced Wnt5a’s
ability to inhibit Wnt3a-induced STF reporter activation
when transfected into 293 cells as compared to cells trans-
fected with the reporters alone (Figure 6D). In addition, when
Ror2-GPI was transfected into cells in conjunction with wild-
type mRor2, mRor2-GPI blocked wild-type mRor29s enhance-
ment of Wnt5a-mediated inhibition, suggesting that the
membrane-tethered variant of mRor2 serves as a dominant
negative. The fact that expression of mRor2-GPI alone did
not enhance Wnt5a-mediated inhibition indicates that the
cytoplasmic, and potentially the transmembrane, domain is
required for mRor2 to carry out its inhibitory function.
To assess the role the mRor2 transmembrane domain plays
in mediating the Wnt5a signal, we created a mRor2 construct
that contains the endogenous extracellular and transmem-
brane domains of the protein but lacks the cytoplasmic
domain (Ror2-TM). We ﬁnd that similar to the mRor2-GPI
construct, expression of Ror2-TM was sufﬁcient to inhibit
wild-type mRor29s ability to enhance Wnt5a signaling (Figure
6E). Unlike the mRor2-GPI construct, however, the mRor2-
TM construct did not reduce Wnt5a’s ability to inhibit
Wnt3a-induced STF reporter activation when transfected
into 293 cells alone. Western blot analysis indicates that wild-
type mRor2 expression is unaffected by cotransfection with
mRor2-GPI or mRor2-TM, further strengthening the idea
that these constructs serve as dominant negative variants of
mRor2. These data taken together suggest that mRor2 does
not simply present Wnt5a to another receptor but rather that
Wnt5a binding initiates Ror2-induced cytoplasmic signaling
events.
Discussion
Due to early overexpression studies in Xenopus embryos, the
Wnts were grouped into various classes based on their
canonical Wnt signaling ability without regard for the cellular
context in which they were overexpressed. Receptor expres-
sion, however, clearly plays a role in determining signaling
output; when coexpressed with the appropriate Fz receptor,
the prototypical ‘‘noncanonical’’ Wnt, XWnt5a, can signal in
a canonical fashion to induce the formation of a secondary
axis [46]. Whereas some have argued that the lack of
functional interaction with LRP distinguishes Wnt5a from
so-called canonical Wnts in mammalian cells [31], previous
studies and our present work conﬁrm that Wnt signaling
output is not intrinsically related to the Wnt protein itself but
rather due to a combination of factors including receptor
availability [41,46].
Several controversies exist in the literature today regarding
the mechanisms by which Wnt proteins signal. Much of the
conﬂicting data, however, can be attributed to the variety of
cellular and organismal systems studied coupled with the
previous lack of soluble, active Wnt proteins. In the case of
Wnt5a, for example, one report has shown that overexpres-
sion of Wnt5a inhibits canonical signaling by promoting the
degradation of b-catenin protein [16]. By contrast, we found
that, in accordance with other groups, Wnt5a protein
treatment has no affect on b-catenin protein levels but
rather inhibits canonical Wnt signaling at the level of TCF
transcription [17,18,33]. Although our data are in agreement
with Wnt5a overexpression studies by Ishitani et al. [17] with
respect to the inhibition occurring downstream of b-catenin
protein stabilization, we found that Wnt5a does not stimulate
Ca
2þ ﬂux and that Wnt5a-mediated inhibition is not sensitive
to pertussis toxin treatment. These data effectively eliminate
G protein–mediated activation of calcium signaling as the
primary mechanism of Wnt5a-mediated inhibition.
Fz receptor signaling capabilities have also often been
debated. Previous studies pertaining to Fz49s role in the
disease familial exudative vitreoretinopathy have suggested
that the Fz4 receptor does not mediate Wnt/b-catenin signal-
ing but rather elicits intracellular calcium ﬂux that sub-
sequently activates downstream calcium effector molecules
[34,40]. By contrast, we show here that in multiple cell lines,
Fz4 allows Wnt5a to speciﬁcally activate TCF/Lef transcription
in the presence of LRP5 and that mFz4 expression does not
enhance calcium ﬂux (Figure 3C). The true signaling
capabilities of the Fz4 receptor may have been previously
overlooked due to the use of an inappropriate Wnt ligand in
the analysis, Wnt1 as opposed to Wnt5a. Additionally, as
calcium signaling capabilities were attributed to Fz4 in the
absence of exogenous ligand stimulation, it remains to be seen
whether Wnt ligands are required for Fz-mediated Ca
2þ ﬂux.
We observe that when mFz4 is overexpressed alone, Wnt5a
protein treatment is sufﬁcient to induce b-catenin protein
stabilization but not STF reporter activation. It is possible
that Wnt5a does not activate a transcriptional response when
mFz4 is expressed alone in 293 cells due to the endogenous
expression of mRor2. In addition, coreceptor expression and
heterodimerization following ligand stimulation have pre-
viously been shown to enhance ligand binding and signal
transduction in other systems [47,48]. As Wnt5a-induced b-
catenin stabilization in cells expressing mFz4 is less robust
than Wnt3a-induced stabilization, overexpression of both
mFz4 and LRP5 may be necessary for full potentiation of the
canonical signal resulting in transcriptional activation.
Furthermore, previous reports have suggested that the
accumulation of b-catenin and Wnt signal transduction are
separable events by showing that b-catenin protein levels
alone do not dictate signal output but rather the phosphor-
ylation state of b-catenin [49,50]. Coexpression of LRP5 may
be necessary for the dephosphorylation, and hence full
activation, of b-catenin resulting in optimal signal trans-
duction.
The disparities between previous reports and our current
observations may be due to the fact that in this study, the
effects of Wnt5a could be monitored immediately following
Wnt5a protein addition as opposed to several hours or cell
divisions following cellular expression, thereby allowing us to
separate early and late effects of Wnt5a treatment. Activation
of downstream transcriptional targets of Wnt5a, such as Siah-
2, may contribute to the overall Wnt5a-mediated inhibition
of Wnt/b-catenin signaling subsequent to the initial signaling
events that we observed [16]. Additionally, in the proposed
Wnt/Ca
2þ signaling model, Wnt5a-stimulated Ca
2þ ﬂux lead-
ing to NLK activation is required for transcriptional
inhibition [17]. However, Wnt1 has recently been shown to
inhibit b-catenin–TCF–mediated transcription via activation
of NLK, although Wnt1 has never been shown to induce Ca
2þ
ﬂux [33]. Thus, Wnt5a may exert its inhibitory effects through
the activation of NLK in a similar Ca
2þ-independent manner.
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Receptor Context Dictates Wnt5a SignalingFurther experimentation into the mechanism by which
Wnt5a inhibits canonical signaling is therefore necessary
and will be addressed in subsequent reports.
In this study, we show that one Wnt ligand can function in
two discreet pathways based on receptor availability (Figure
7). Data in the literature suggest that this may also apply to
other Wnts. For example, Wnt1 is known to activate canon-
ical Wnt signaling through b-catenin and TCF and act as an
oncogene [51]. However, using overexpression in various cell
lines, Smit et al. presented evidence that Wnt1 inhibits TCF
activity [33]. Another example is Wnt11, which has been
implicated in the noncanonical convergence-extension path-
way in zebraﬁsh [52]. Recent work, by contrast, demonstrates
that Wnt11 is the long-sought ligand that activates the b-
catenin pathway in the early Xenopus embryo, showing that
one Wnt can activate two different pathways, possibly also by
activating different receptors [53].
Although the ability of one Wnt ligand to function in two
distinct pathways based on receptor context is novel for the
Wnt ﬁeld, we note that in an entirely different system,
opposing effects brought about by a single ligand have also
been explained by the use of different receptor classes. This
example is formed by the Netrins, ligands that can either
attract or repel axons depending on whether they interact
with the DCC (deleted in colorectal carcinoma) or UNC5
(UNCoordinated family member 5) families of receptors [54–
56]. Thus, ligands engaging multiple receptors to effect
different signaling outcomes is not unprecedented in nature.
With as many as 19 mammalian homologs known, the
question of whether all Wnt family members have evolved to
signal in the same fashion is an important one. In this report,
we address controversies in the literature regarding how one
Wnt family member, Wnt5a, functions. Through quantitative
kinetic analyses, we provide evidence for the ﬁrst time that
Wnt5a protein can directly inhibit canonical Wnt/b-catenin
signaling and that the single-pass transmembrane receptor
Ror2 is required to mediate this activity. Although Wnt5a can
inhibit canonical Wnt signaling when Ror2 is expressed at
detectable levels, Fz 4 and LRP5 coreceptor expression allows
Wnt5a to signal in a canonical fashion. This ability of Wnt5a
to toggle between two considerably diverse forms of signaling
is particularly intriguing when one considers that Wnt5a has
been classiﬁed as both a tumor suppressor and an oncogene
in various cell types [57–59]. While previously somewhat
paradoxical, it is now clear that in the former role, Wnt5a
expression may inhibit uncontrolled Wnt/b-catenin signaling
in the presence of Ror2, whereas in the latter, Wnt5a could
promote canonical Wnt signaling when Fz4 and LRP5 are
expressed. Future study into speciﬁc receptor-ligand inter-
actions will thus contribute to understanding the complex-
ities of Wnt signaling.
Materials and Methods
Wnt5a puriﬁcation. Wnt5a protein was puriﬁed from 6 L of media
conditioned by mouse L cells stably overexpressing mouse Wnt5a
(CRL-2814; American Type Culture Collection [ATCC], Manassas,
Virginia, United States) created in the laboratory as previously
described [27] with the addition of a fourth puriﬁcation step. Brieﬂy,
following a gel ﬁltration sizing step, partially puriﬁed Wnt5a protein
was bound to a copper-chelated resin and eluted with increasing
concentrations of Imidazole (HiTrap Chelating HP; Amersham
Biosciences, Little Chalfont, United Kingdom). Peak fractions were
then further puriﬁed by heparin afﬁnity chromatography as
previously described. Typical yields of Wnt5a protein following ﬁnal
heparin afﬁnity step range from 25 to 50 ng/ll as assessed by
Coomassie blue staining.
CRD protein puriﬁcation. Serum-free media conditioned from 293
cells stably secreting CRD-IgG proteins was collected and bound to a
Hitrap Protein A HP 1-ml column (Amersham Biosciences). Bound
proteins wereeluted with 100 mM citric acid (pH3.0) and immediately
madepHtoneutralwith800mMHEPES,300mMNaCl(pH7.5)buffer
supplementedwithproteaseinhibitors.Proteinfromthepeakfraction
wasincubated withproteinA–Sepharose beads for4 h at4 8Cand then
washed 4 times with TNT buffer (see below). CRD-bound beads then
incubated overnight at 4 8C with Wnt proteins. Beads were washed 4
times with TNT buffer, brought up in sample buffer, and analyzed for
coimmunoprecipitation via Western blotting.
cDNA constructs and antibodies. pcDNA3-mRor2 and
mRor2DCRD constructs were obtained from the Minami lab [23].
We generated the mRor2 CRD-IgG construct by fusing the Fz8 signal
sequence (bases 1 to 100) to the mRor2 CRD (bases 505 to 909 of the
complementary DNA of mRor2) in frame with IgG as previously
described [43]. The mRor2NT CRD-IgG construct corresponds to
bases 1 to 909 of mRor2 fused to IgG. pRK5-mRor2-GPI construct was
generated by fusing bases 1 to 1221 of mRor2 in frame to DAF-GPI.
pRK5-DAF-GPI fusion protein vector was provided by the Nathans
lab [43]. pEF1-mRor2-TM corresponds to bases 1 to 1303 of mRor2.
Human LRP5 and LRP6 constructs in the CS2þvector were obtained
from the He lab [60]. pcDNA3.1- Fz 4 (FLAG-tagged) was provided by
the Lefkowitz lab [15]. Fz 8 complementary DNA was subcloned into
the pEF1-myc/his A vector (Invitrogen, Carlsbad, California, United
States) and pEF1a-LacZ (Invitrogen) was used for b-galactosidase
activity normalization. STF was obtained from the Moon lab [30]. All
DNA segments generated by PCR were sequenced to rule out
spurious mutations.
Figure 7. Model. Wnt5a Can Activate or Inhibit Canonical Wnt Signaling
Depending on Receptor Context
In the presence of Fz4 and LRP5, Wnt5a can activate b-catenin/TCF
signaling. However, when Ror2 is expressed, Wnt5a inhibits canonical
Wnt signaling downstream of b-catenin stabilization, at the level of TCF-
mediated transcription.
DOI: 10.1371/journal.pbio.0040115.g007
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Receptor Context Dictates Wnt5a SignalingAntibodies were used at the following concentrations: rabbit anti-
Wnt5A (1:1,000), rabbit anti-Fz4 (1:1,000), mouse 9E10 (1:200;
Developmental Studies Hybridoma Bank at the University of Iowa,
Iowa City, Iowa, United States), mouse anti-b-catenin (1:500; Santa
Cruz Biotechnology, Santa Cruz, California, United States), mouse
anti-GSK-3b (1:2,000; Transduction Labs, BD Biosciences Pharmin-
gen, San Diego, California, United States), anti-phospho p44/p42
(1:1,000, Cell Signaling Technology, Beverly, Massachusetts, United
States), and anti-total p44/p42 (1:1,000; Cell Signaling Technology).
Proteins were detected using HRP-conjugated secondary antibodies
(Santa Cruz Biotechnology) with ECL Western blot detection reagents
(Amersham Biosciences). Anti-mouse Wnt5a antibody was generated
by cloning a 167–base pair fragment corresponding to bases 757 to
924 of the complementary DNA of mWnt5a into the pGEX4T-1
vector. Puriﬁed mWnt5a-GST fusion protein was then injected into a
rabbit following standard procedures (Josman Laboratories). The
ﬁnal bleed was subsequently afﬁnity puriﬁed.
Cell culture, mammalian cell transfection, and luciferase assays.
HEK293 cells, mouse L cells, and their variants were cultured in
DMEM, 10% FBS, and antibiotics.
To generate cell lines stably expressing Fz receptors, cells grown on
10-cm plates were transfected using LipofectAMINE2000 according
to the manufacturer’s instructions (Invitrogen). At 24 h post-trans-
fection, cells were plated out in limiting dilution and cultured under
neomycin selection (1 mg/ml G418) for 10 to 14 d. At least 20 single
cell clones were screened for expression via Western blot analysis.
Transient transfections were performed with LipofectAMINE2000
(Invitrogen) on 293 cells, L cells, or stable cell line variants in six-well
plates. Empty vector, CS2þ-hLrp5, pcDNA3-mRor2, or derivatives
were transfected (1 lg/well) together with the STF luciferase reporter
(1 lg/well) and b-galactosidase (0.33 lg) (pEF-1a-LacZ; Invitrogen)
plasmids. At 24 h post-transfection, cells were replated into a 96-well
plate, allowed to recover for 6 to 8 h, and then treated in duplicate or
triplicate with Wnt proteins as described in the text. Luciferase assays
were performed using Dual-Light reporter gene assay system
(Applied Biosystems). Relative luciferase units were measured and
normalized against b-galactosidase activity at 48 h post-transfection.
Error bars represent standard deviation, and each assay was
performed at least two times.
Cell extraction and Western blotting. For assaying Fz expression,
cells were lysed in TNT buffer on ice (50 mM Tris-HCl, 150 mM NaCl,
1% Triton X-100). After clearing lysates with high-speed spin, protein
supernatants were diluted into SDS sample buffer. In Erk1,2
phosphorylation assays, cells were lysed in hot sample buffer (62.5
mM Tris, 2% SDS, 10% glycerol, 50 mM DTT, 0.01% bromophenol
blue) supplemented with protease inhibitors (Complete Inhibitors;
Roche, Basel, Switzerland) and then passaged 10 times through a 25-
gauge syringe. For visualization of b-Catenin accumulation in 293
cells, cells were lysed by hypotonic lysis: cells were scraped into
hypotonic buffer (10 mM Tris-HCl, 0.2 mM MgCl2 [pH 7.4])
supplemented with protease and phosphatase inhibitors, incubated
on ice for 10 min, and homogenized using a tight-ﬁtting glass dounce.
Sucrose and EDTA were added to ﬁnal concentrations of 0.25 M and
1 mM, respectively. Lysates were then centrifuged at 20,0003g for 1 h
at 4 8C. Supernatant representing cytosolic cell fraction was then
diluted into SDS sample buffer.
For immunoblotting, samples were resolved on SDS-10% poly-
acrylamide gels and transferred to nitrocellulose. The membranes
were incubated for 1 h in blocking solution (1% BSA, 3% nonfat dry
milk in Tris-buffered saline containing 0.2% Tween-20) and then
overnight at 4 8C with antibody in blocking solution.
Quantitative RT-PCR analysis. Qiagen RNeasy midi-kit (Valencia,
California, United States) was used with on-column DNase step to
prepare total RNA from each cell line. Then 1 lg of total RNA was
converted to cDNA using random hexamer priming (Thermoscript
RT-PCR System; Invitrogen). Quantitative real-time PCR analysis was
performed in a Roche LightCycler 2.0 using LightCycler FastStart
DNA Master
PLUS SYBR Green I kit (Roche) with 0.5 ll of prepared
cDNA and 0.5 lM forward and reverse primers per reaction. The
primers for real-time PCR were designed using LightCycler Probe
Design Software 2.0. Following 45 cycles of ampliﬁcation, Ror2
expression in each cell line was normalized to HPRT expression
following primer efﬁciency analysis. Reactions were performed in
triplicate at least two times.
Primers used. Primers used were human Ror2 F: 59-ATGGAACT
GTGTGACGTACCC-39; mouse Ror2 F: 59-TGGAACTGTGTGACG-
TACCC-39; human/mouse Ror2 R: 59-GCGAGGCCATCAGCTG-39;
human HPRT F: 59-CAAGTTTGTTGTAGGATATGCCC-39; human
HPRT R: 39-CGATGTCAATAGGACTCCAGA-39; mouse HPRT F: 59-
TGTTGTTGGATATGCCCTTG-39; and mouse HPRT R: 39-
TTGCGCTCATCTTAGGCTTT-39.
Immunoﬂuorescence staining. For immunoﬂuorescence micro-
scopy, cells were grown on glass coverslips, ﬁxed with 4%
paraformaldehyde at 4 8C for 10 min, and permeabilized in methanol
at 20 8C for 20 sec. The coverslips were then exposed to primary
antibodies, followed by Cy3-conjugated secondary antibodies. Slides
were mounted with Vectashield mounting media with Dapi (Vector
Laboratories, Burlingame, California, United States) and ﬂuorescence
examined with a Zeiss Axioplan 2 microscope.
Calcium ﬂux assays. The 293 cells plated onto glass chamber slides
(Nalge Nunc International, Rochester, New York, United States) were
loaded with 1 lM fura-2 AM (Molecular Probes, Eugene, Oregon,
United States) for 20 min prior to imaging. The cells were washed and
then imaging was carried out on a previously described microscope
system [61]. For time-lapse experiments, image pairs were collected at
340- and 380-nm excitation wavelength (510-nm emission) at 15-s
intervals for 15 min following the addition of Wnt5a protein (500 ng/
ml). Following Wnt protein incubation, cells were treated with
ionomycin (1 lM) and immediately imaged for an additional 5 min.
The ratio image, a pixel-by-pixel match of both excitation wave-
lengths, was calculated by computer software and the sequence of
ratio images was processed. Microscope control, data acquisition, and
image analysis were performed in MetaMorph (Universal Imaging,
Molecular Dynamics, Sunnyvale, California, United States).
Supporting Information
Figure S1. mRor2 Enhances Wnt5a-Mediated Inhibition of Canonical
Wnt Signaling
(A–C) Although Wnt5a protein shows inhibitory activity in 293 cells,
it does not inhibit the STF reporter in 293Fz4 cells. Wnt5a-mediated
inhibition is enhanced when mRor2 is stably expressed. At 24 h post-
transfection, 293, 293Fz4, and 293Ror2 cells were treated with Wnt
proteins for the indicated time points. Data are represented as
relative light units (RLUs) 6 SD rather than as average fold change.
Found at DOI: 10.1371/journal.pbio.0040115.sg001 (140 KB PDF).
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